Cost–Consequence Analysis of Nitisinone for Treatment of Tyrosinemia Type I

BACKGROUND: Tyrosinemia type I is a rare but severe genetic metabolic disorder. Nitisinone combined with a diet low in tyrosine and phenylalanine became first-line therapy in 1994. OBJECTIVES: To estimate the direct medical costs of health care services related to the treatment of tyrosinemia type I...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Can J Hosp Pharm
Hlavní autoři: Simoncelli, Mariève, Samson, Johanne, Bussières, Jean-François, Lacroix, Jacques, Dorais, Marc, Battista, Renaldo, Perreault, Sylvie
Médium: Artigo
Jazyk:Inglês
Vydáno: Canadian Society of Hospital Pharmacists 2015
Témata:
Original Research / Recherche Originale
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4485508/
https://ncbi.nlm.nih.gov/pubmed/26157182
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky